BRIEF-Abivax Presents First Quarter 2026 Financial Results

Abivax SA Sponsored ADR

Abivax SA Sponsored ADR

ABVX

0.00

May 22 (Reuters) - Abivax SA ABVX.PA:

  • ABIVAX PRESENTS FIRST QUARTER 2026 FINANCIAL RESULTS AND REPORTS THREE-YEAR INTERIM DATA FROM STUDY 108, A PHASE 2A/2B OPEN-LABEL EXTENSION TRIAL OF OBEFAZIMOD FOLLOWING DOSE DE-ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS

  • ABIVAX SA - REPORTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF €491.6 MILLION AS OF MARCH 31, 2026

  • ABIVAX SA - Q1 2026 OPERATING LOSS WAS €56.2 MILLION

  • ABIVAX SA - Q1 NET LOSS 48.5 MILLION EUROS

Source text: ID:nGNXf949j

Further company coverage: ABVX.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.